Medicus Pharma Ltd. (MDCXW) company profile
Close on Oct 30, 2026Market cap $118.78MP/E –Yield –
About Medicus Pharma
Pharmaceutical Preparations, SIC 2834
Medicus Pharma Ltd. is a clinical-stage biotechnology company that identifies, acquires, and develops therapeutic assets through Phase 2 proof-of-concept. The company seeks to out-license these programs or establish strategic partnerships with pharmaceutical companies for late-stage development and commercialization. Its core development programs operate through subsidiaries SkinJect Inc. and Antev. SkinJect develops doxorubicin-containing dissolvable microneedle arrays as localized treatments for non-melanoma skin conditions, primarily basal cell carcinoma. Antev develops Teverelix, an injectable gonadotrophin-releasing hormone antagonist designed for individuals with advanced prostate cancer and high cardiovascular risk, as well as patients experiencing acute urinary retention episodes due to enlarged prostate.
The company operates across multiple countries located across three continents, with clinical trial activities conducted in the United States and the United Arab Emirates, alongside clinical study approvals in the United Kingdom. Medicus Pharma Ltd. does not report any physical headquarters location in the provided text.
Summary of the business section of Medicus Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Medicus Pharma Ltd.
- Founded
- 2008
- Headquarters
- W. Conshohocken, PA
- Address
- 300 Conshohocken State Rd., Suite 200 19428
- Phone
- (610) 540-7515
- Website
- medicuspharma.com
- Employees
- 16, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A6
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, New York, New York
Stock & identifiers
- Ticker
- MDCXW
- Other tickers
- MDCX
- Exchange
- Nasdaq
- IPO date
- Nov 15, 2024
- Shares outstanding
- 63M, Aug 10, 2026
- Public float
- $28.30M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Oct 12, 2026
- SEC CIK
- 1997296
- CUSIP
- 58471K111
- ISIN
- CA58471K1113
- FIGI
- BBG01QS1GG41
- EIN
- 98-1778211
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Raza Bokhari | Chief Executive Officer, Director | 3,734,349 |
| Andrew Alasdair Smith | Chief Operating Officer | 735,458 |
| Carolyn F. Bonner | President and CFO | 1,489,493 |
| Edward J. Brennan | Chief Scientific Officer | 674,735 |
| Faisal Mehmud | Chief Medical Officer | 1,470,588 |
| James P. Quinlan | Chief Financial Officer | 274,147 |
| Patrick J. Mahaffy | Director | 35,435 |
| William Ashton | Director | 1,250 |
| Barry Fishman | Director | – |
| Ajay Raju | Director | – |
| Robert J. Ciaruffoli | Director | 12,500 |
| Sara R. May | Director | – |
| Larry Kaiser | Director | – |
| Cathy McMorris Rodgers | Director | – |
| Frank W. Lavelle | Director | 25,622 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Dr. Raza Bokhari Chief Executive Officer | – | $405.86K | $226.81K | $632.68K | +297% |
| Carolyn Bonner Chief Financial Officer and President | $310.00K | $83.76K | $29.89K | $423.65K | +327% |
| Dr. Faisal Mehmud Chief Medical Officer | $333.50K | $287.67K | $204.93K | $826.10K | +1676% |
| Dr. Edward Brennan Chief Scientific Officer & Head of R&D Program | $337.00K | $110.22K | $142.42K | $589.63K | +12% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 15, 2024
- Offer price
- $4.13
- Securities offered
- 970,000
- Gross proceeds
- $4.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- May 14, 2025
“Per Unit Total Initial public offering price $4.125 $4,001,250 Underwriting discounts and commissions (1) $0.309 $299,730 Proceeds, before expenses $3.816 $3,701,520 (1) We have also agreed to reimburse the underwriters for certain expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this annual report, including our subsidiaries, we have 16 employees, all of which are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 23, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 27, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Apr 24, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 2, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 5, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Nov 15, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 14, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |